Next generation sequencing: implications in personalized medicine and pharmacogenomics

2016 ◽  
Vol 12 (6) ◽  
pp. 1818-1830 ◽  
Author(s):  
Bahareh Rabbani ◽  
Hirofumi Nakaoka ◽  
Shahin Akhondzadeh ◽  
Mustafa Tekin ◽  
Nejat Mahdieh

A breakthrough in next generation sequencing (NGS) in the last decade provided an unprecedented opportunity to investigate genetic variations in humans and their roles in health and disease.

2021 ◽  
Vol 18 (4) ◽  
pp. 26-32
Author(s):  
V. M. Mitsura

This review presents basic principles and methods of next-generation sequencing (NGS) and discusses a number of the latest papers on the possibilities, principles and stages of NGS, as well as the application of NGS in medical research, particularly, clinical microbiology and infectious diseases, epidemiology. The development of NGS technologies will allow improving the results of diagnostics, treatment and prevention of infectious diseases and opens up new prospects for personalized medicine.


2014 ◽  
Vol 4 (2) ◽  
pp. 45-48
Author(s):  
Ramzi Hassouneh

Next-generation sequencing (NGS) has ignited a revolution in genomic medicine by eliminating the inherent limitations of conventional sequencing methods. Due to its high throughput and low-cost, clinics can use NGS to perform targeted and genome sequencing to make diagnoses or pre-screen for risk to future disease. Despite its clinical uses, many challenges exist before NGS becomes a mainstay in the clinic. There is a lack of understanding of the impact of genetic variants on health and disease and how to best apply genetic information to patient care. Nevertheless, the translation of base pair reads to clinical applications has truly begun.


2020 ◽  
Vol 10 (1) ◽  
pp. 34
Author(s):  
Alireza Tafazoli ◽  
Natalia Wawrusiewicz-Kurylonek ◽  
Renata Posmyk ◽  
Wojciech Miltyk

Pharmacogenomics (PGx) is the knowledge of diverse drug responses and effects in people, based on their genomic profiles. Such information is considered as one of the main directions to reach personalized medicine in future clinical practices. Since the start of applying next generation sequencing (NGS) methods in drug related clinical investigations, many common medicines found their genetic data for the related metabolizing/shipping proteins in the human body. Yet, the employing of technology is accompanied by big obtained data, which most of them have no clear guidelines for consideration in routine treatment decisions for patients. This review article talks about different types of NGS derived PGx variants in clinical studies and try to display the current and newly developed approaches to deal with pharmacogenetic data with/without clear guidelines for considering in clinical settings.


Sign in / Sign up

Export Citation Format

Share Document